EOLS vs NMAI Comparison

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.